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Identification and Clinical Implications of Novel 
MYO15A Mutations in a Non-consanguineous 
Korean Family by Targeted Exome Sequencing 
 
Mun Young Chang2,7, Ah Reum Kim2,7, Nayoung K.D. Kim3, Chung Lee3,4, Kyoung Yeul Lee5, Woo-Sung Jeon5,  
Ja-Won Koo1, Seung Ha Oh2, Woong-Yang Park3,4,6, Dongsup Kim5, and Byung Yoon Choi1,* 
 
 
Mutations of MYO15A are generally known to cause severe 
to profound hearing loss throughout all frequencies. Here, 
we found two novel MYO15A mutations, c.3871C>T 
(p.L1291F) and c.5835T>G (p.Y1945X) in an affected indi-
vidual carrying congenital profound sensorineural hearing 
loss (SNHL) through targeted resequencing of 134 known 
deafness genes. The variant, p.L1291F and p.Y1945X, re-
sided in the myosin motor and IQ2 domains, respectively. 
The p.L1291F variant was predicted to affect the structure 
of the actin-binding site from three-dimensional protein 
modeling, thereby interfering with the correct interaction 
between actin and myosin. From the literature analysis, 
mutations in the N-terminal domain were more frequently 
associated with residual hearing at low frequencies than 
mutations in the other regions of this gene. Therefore we 
suggest a hypothetical genotype-phenotype correlation 
whereby MYO15A mutations that affect domains other than 
the N-terminal domain, lead to profound SNHL throughout 
all frequencies and mutations that affect the N-terminal do-
main, result in residual hearing at low frequencies. This 
genotype-phenotype correlation suggests that preservation 
of residual hearing during auditory rehabilitation like coch-
lear implantation should be intended for those who carry 
mutations in the N-terminal domain and that individuals with 
mutations elsewhere in MYO15A require early cochlear im-
plantation to timely initiate speech development.1 
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INTRODUCTION 
 
Nonsyndromic hearing loss (NSHL) accounts for 70% of here-
ditary hearing loss, and most NSHL (~80%) is inherited in an 
autosomal recessive fashion (Hilgert et al., 2009). The DFNB3 
locus, which is implicated in autosomal recessive congenital 
deafness (OMIM 600316), was first identified in families from 
an Indonesian village (Friedman et al., 1995). This locus was 
mapped to the 17p11.2 chromosome region in this population 
(Liang et al., 1998). A subsequent study revealed MYO15A 
(MIM# 600316, NM_016239) to be the causative gene of 
DFNB3 (Wang et al., 1998). 
MYO15A has 66 coding exons and encodes a 3,530-amino-
acid protein. Depending on the presence of exon 2, which en-
codes an N-terminal extension, myosin XVA has two isoforms; 
class 1 and class 2 (Liang et al., 1999). The class 1 isoform is 
composed of an N-terminal domain, a motor head domain, a 
neck region and a tail region. The neck region contains three 
light chain-binding motifs (IQ). The long tail region contains two 
myosin tail homology 4 (MyTH4) domains, two F, ezrin, radixin, 
and moesin (FERM) domains, an SH3 domain and a C-
terminal PDZ binding motif (Berg et al., 2001; Garcia-Alvarez et 
al., 2003; Krendel and Mooseker, 2005; Liang et al., 1999). The 
class 2 isoform, which has no N-terminal domain, is also 
present in the human inner ear (Liang et al., 1999). 
Myosin XVa plays a crucial role in the graded elongation of 
stereocilia (Abecasis et al., 2001; Belyantseva et al., 2003; 
Krendel and Mooseker, 2005) and actin-organization in inner 
ear hair cells (Berg et al., 2001; Wang et al., 1998), which are 
vital for sound transduction. Myosin XVa is therefore an essen-
tial component of normal auditory function. The effects of muta-
tions in MYO15A on hearing have been investigated extensive-
ly. MYO15A mutations have been regarded as leading to con-
genital severe to profound hearing loss (Belguith et al., 2009; 
Brownstein et al., 2011; Gao et al., 2013; Kalay et al., 2007; 
Liburd et al., 2001; Shearer et al., 2009; Wang et al., 1998). In 
contrast, it was also reported that a mutation in exon 2 of 
MYO15A resulted in some residual hearing (Bashir et al., 2012; 
Cengiz et al., 2010; Nal et al., 2007), especially at low frequen-
cies, suggesting that there may be a genotype-phenotype cor-
relation. 
Here, we report two novel MYO15A mutations identified by 
targeted exome sequencing from a non-consanguineous Ko-
rean family, showing congenital profound sensorineural hearing 
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Fig. 1. Pedigree, auditory steady state response (ASSR) and segregation of the c.3871C>T and c.5835T>G variants of MYO15A in family 
SB156. (A) Targeted sequencing was performed for one affected individual (red diamond). An additional two affected individuals (circles) were 
recruited for Sanger validation and further analyses. (B) The ASSR test revealed that the average hearing threshold of SB156-272 was 100 dB 
at 4 and 10 months of age. (C) Sanger sequencing traces for the c.3871C>T (p.L1291F) + c.5835T>G (p.Y1945*) compound heterozygote 
(SB156-272). (D) Sanger sequencing traces for the c.5835T>G carrier (SB156-327). (E) Sanger sequencing traces for the c.3871C>T carrier 
(SB156-328). (F) Conservation of mutant residues among orthologs from several species; p.L1291 is conserved among all species, ranging 
from humans to zebrafish. (G) The sequence variants c.3871C>T and c.5835T>G reside in exon 6 (motor domain) and exon 24 (IQ2 domain) 
of MYO15A, respectively (adapted from Nal et al., 2007). 
 
 
 
loss (SNHL). Based on our observations, which are compatible 
with previous suggested genotype-phenotype correlations for 
MYO15A, we propose how this finding can be utilized clinically 
as regards early bilateral cochlear implantation and residual 
hearing preservation during cochlear implantation. 
 
MATERIALS AND METHODS 
 
Human subjects 
All procedures in this study were approved by the Institutional 
Review Boards at Seoul National University Hospital (IRBY-H-
0905-041-281) and Seoul National University Bundang Hospital 
(IRB-B-1007-105-402). Written informed consent was obtained 
from all individuals (or guardians, in the case of children). One 
family (SB156), which showed profound SNHL in an autosomal 
recessive fashion, was included in this study. The family 
(SB156) comprised 12 individuals, 3 of whom participated in 
the study. The family members (SB156-272, 327 and 328) 
covered two generations and were evaluated at Seoul National 
University Bundang Hospital (Fig. 1A). Phenotypic evaluations 
included medical and developmental history interviews, physi-
cal examinations, and audiometric evaluation.  
 
Audiometric evaluation 
Auditory steady state response (ASSR), auditory brain stem 
response threshold (ABRT) and distortion product otoacoustic 
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Fig. 2. Schematic flow chart of the filtering of causative variants in 
this study 
 
 
 
emission (DPOAE) tests were carried out on SB156-272 at 4 
and 10 months of age. The ASSR results are shown in Fig. 1B. 
Temporal bone computed tomography (CT) and internal audito-
ry canal magnetic resonance image (MRI) of SB156-272 were 
used to identify any inner ear anomalies related to the hearing 
loss. 
 
Molecular genetic testing  
Targeted resequencing and bioinformatics analyses were per-
formed as described previously (Choi et al., 2013). DNA sam-
ples from SB156-272 were subjected to targeted resequencing 
of 134 known deafness genes (TRS-134) by Otogenetics 
(USA) (Supplementary Table S1). The acquired reads were 
mapped onto the UCSC hg19 reference genome. Further bioin-
formatics analyses were performed to identify variants. As a 
basic filtering step, non-synonymous single nucleotide poly-
morphisms (SNPs) with read depths >40 were chosen. These 
non-synonymous SNPs were compared against an in-house 
database, an independent cohort consisting of 54 normal Ko-
rean individuals and the Single Nucleotide Polymorphism Da-
tabase (dbSNP build 138). Only novel SNPs or known disease-
causing SNPs remained. Inheritance patterns were checked 
and SNPs that did not coincide with an autosomal recessive 
pattern were excluded. The remaining SNPs were validated in 
other family members (SB156-327 and SB156-328) by Sanger 
sequencing. The SNPs were also checked against an addition-
al 426 unrelated Korean control chromosomes (Fig. 2). 
To predict the pathogenicity of the missense variants, SIFT 
and PolyPhen-2 analyses were carried out. The evolutionary 
conservation of the amino acid sequence was estimated using 
the GERP++ score in the UCSC Genome Browser (http://  
genome.ucsc.edu/). 
 
Three-dimensional protein modeling of the motor domain 
of myosin XVA  
To assess the pathogenicity of a candidate variant in the motor 
domain of myosin XVA, three-dimensional protein modeling of 
the motor domain was performed. Since there is no known 3D 
structure of motor domain of MYO15A in the Protein Data Bank, 
the structure for motor domain of MYO15A was built using the 
homolog modeling method (BLAST, http://blast.ncbi.nlm.nih. 
gov/Blast.cgi/; HHpred, http://toolkit.tuebingen.mpg.de/hhpred/; 
PDB, http://pdb.org/pdb/home/home.do/; UNIPROT. http://www. 
uniprot.org/). The template structure that was sequentially most 
similar to the motor domain of myosin XVA using BLAST and 
HHPred was sought, and the myosin II heavy chain from Dic-
tyostelium discoideum (pdb ID: 1W9J A) was selected. The 
sequence identity between this chain and human myosin XVA 
was 44%. The structure model of human myosin was built us-
ing MODELLER, a homology-modeling software package 
(Eswar et al., 2006). A mutant model was also constructed from 
the wild type structure model using FoldX (http://foldx.crg.es/). 
To ensure the quality of the models, the wild type and mutant 
models were examined using the Pymol visualization tool 
(http://www.pymol.org/). 
 
Analysis of audiologic features of MYO15A mutations 
We tried to delineate any correlation between the locations of 
MYO15A mutations and the audiotory phenotype, relying on 
the audiograms available in the literature. In case audiogram 
was unavailable, description about auditory phenotype was 
used. Subjects without audiogram or description were excluded 
from the analysis. A literature search was made in Pubmed 
covering the period 2001 to 2014. Subjects with MYO15A mu-
tations were divided into two groups, with mutations in the N-
terminal domain or in the other regions. The frequency of sub-
jects with residual hearing, of which thresholds were better than 
70dB HL at any frequency, was calculated in each group. 
 
RESULTS 
 
Auditory phenotype and cochlear implantation 
SB156-272 showed no response to 90 dB click sounds at 4 
and 10 months of age in ABRT testing. ASSR testing using 
louder stimuli revealed an average threshold of 100 dB for 
SB156-272 at 4 and 10 months. There was no change in the 
hearing ability of SB156-272 over the 6-month follow-up period. 
The guardians of SB156-272 denied any exposure to risk fac-
tors such as drugs or loud noises. No syndromic features were 
detected in the physical examination. Temporal bone CT and 
internal auditory canal MRI revealed no abnormal findings. 
SB156-272 had started wearing hearing aids in both ears at 5 
months and underwent simultaneous bilateral cochlear implan-
tation at 11 months. 
 
Targeted resequencing data analysis 
Targeted resequencing was performed in SB156-272. The 
reads were aligned to a human reference genome. Bioinformat-
ics analyses were carried out as mentioned above (Fig. 2). 
Following the basic filtering step, 19 SNPs were selected as 
candidate mutations (Supplementary Table S2). The inherit-
ance pattern of the family was regarded as autosomal reces-
sive (Fig. 1A) and SNPs that did not fit with an autosomal re-
cessive inheritance pattern were excluded. Candidate variants 
were validated by Sanger sequencing in the parents of SB156-
272 (SB156-327 and SB156-328). Two candidate variants from 
a single gene, MYO15A, remained (Table 1). These were 
c.3871C>T (p.L 1291F) in exon 6 and c.5835T>G (p.Y1945*) in 
exon 24 (Fig. 1C). The mother of SB156-272 (SB156-328) was 
heterozygous for c.3871C>T (p.L1291F) and the father (SB156- 
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Fig. 3. The location of the p.L1291F mutation 
(blue) is close to two functionally important bind-
ing sites; the ATP-binding site (red) and the 
actin-binding site (yellow). 
Table 1. Causal Variant MYO15A 
Patient Gene Variant annotation 
Inheritance 
mode of the 
variant 
Chr Ref Var Depth P not ref Q call GERP Score Classification
B156-272 MYO15A NM_016239:exon6:c.3871C> 
T:p.Leu1291Phe 
AR 17 C T 60 100.00% 60 5.01 Nonsynonymous
 
  NM_016239:exon24:c.5835T> 
G:p.Tyr1945* 
AR 17 T G 81 100.00% 60  Nonsense 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
327) was heterozygous for c.5835T>G (p.Y1945*) (Figs. 1D 
and 1E). These two variants were not found in 426 control 
chromosomes from unrelated Koreans with normal hearing. In 
addition, the SIFT and Polyphen-2 analyses consistently identi-
fied the MYO15A c.3871C>T (p.L1291F) SNP as “damaging.” 
Furthermore, p.L1291 was well-conserved in several species, 
as indicated by the high GERP++ score of 5.01 (Fig. 1F). 
These results strongly supported the pathogenicity of the con-
version of leucine to phenylalanine at residue 1291 of myosin 
XVA. The c.3871C>T and c.5835T>G mutations resided in the 
myosin motor and IQ2 domains, respectively. The p.Y1945* 
was the second mutation detected in the IQ2 domain (Fig. 1G).  
 
Three-dimensional protein modeling of myosin XVA 
The p.L1291F model was constructed from the wild-type struc-
ture model using FoldX by replacing p.L1291 with phenylala-
nine. The p.L1291F mutation was evaluated by comparing that 
of the wild type to the mutant model. Visual inspection of the 
three-dimensional structure revealed that the mutation site, 
although it was distant from the actin binding region (from 1972 
to 1799) in terms of protein sequence, was located near the 
actin binding region which is crucial to the proper function of 
myosin (Fig. 3). In particular, mutations at this site would alter 
the position of the actin-binding region. As phenylalanine is 
larger than leucine, p.L1291F would push away the actin-
binding region as a result of direct contact between p.F1291 
and p.M1793 (Figs. 4A and 4B). This structural change in the 
actin-binding region would decrease the binding stability be-
tween actin and the myosin motor domain, which would have a 
detrimental effect on the interaction between actin and myosin. 
 
Analysis of audiologic features of MYO15A mutations 
From the analysis of literature, 9 (64.2%) of 14 subjects with 
mutations in the N-terminal domain showed significant residual 
hearing of which thresholds were better than 70dB HL especial-
ly at low frequencies. In contrast, among 93 subjects harboring 
mutations in the other regions of this gene, only one (1.0%) 
subjects retained a significant residual hearing, while the others 
were associated with severe to profound hearing loss through-
out all frequencies. Therefore, mutations in the N-terminal do-
main of MYO15 were more frequently associated with less 
severe hearing loss than were mutations in the other regions of 
this gene (Fisher’s exact test, P < 0.001) (Table 2). 
 
DISCUSSION 
 
Myosin belongs to the superfamily of actin-dependent molecular 
motors, and facilitates the movement of actin filaments via the 
force generated by hydrolysis of adenosine triphosphate (ATP) 
(Kim et al., 2008; Krendel and Mooseker, 2005; Mooseker and 
Cheney, 1995). Myosin consists of three evolutionarily con-
served domains: the motor domain, the neck region, and the 
tail region. The major structural components of the motor do-
main are highly conserved. The neck region includes one or 
more light-chain-binding IQ motifs. The tail region is diverse in 
length and sequence (Friedman et al., 1999). The myosin su-
perfamily is subdivided into 1 conventional and 20 unconven-
tional classes, based on the amino acid sequence variation of 
the motor domain (Berg et al., 2001; Krendel and Mooseker, 
2005). Two conventional myosins; MYH9 and MYH14, and five 
unconventional myosins; Ia, IIIa, VI, VIIa and XVa are important 
in normal auditory function. Mutations in the genes encoding 
these myosins are responsible for hearing loss (Donaudy et al., 
2003; 2004; Friedman et al., 1999; Lalwani et al., 2000; Walsh 
et al., 2002). 
Among the myosin superfamily, changes in the unconven- 
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Table 2. Auditory Phenotype According to The Affected Domain 
Nucleotide change Amino acid change 
Affected 
domain 
Inheritance Hearing loss Reference 
c.867C>G p.Tyr289* N-terminal Homozygous *Residual hearing at low frequency Cengiz et al., 2010 
c.867C>G p.Tyr289* N-terminal Homozygous Profound Cengiz et al., 2010 
c.1185dup p.Glu396Argfs*36 N-terminal Homozygous *Residual hearing at low frequency Bashir et al., 2012 
c.3313G>T p.Glu1105* N-terminal Homozygous Severe to profound Nal et al., 2007 
c.3336del p.Arg1113Valfs*12 N-terminal Homozygous *Residual hearing at low frequency Nal et al., 2007 
c.3685C>T p.Gln1229* Motor Homozygous Profound Liburd et al., 2001 
c.3756+1G>T   Homozygous Profound Liburd et al., 2001 
c.3758C>T p.Thr1253Ile Motor Homozygous Severe to profound Nal et al., 2007 
c.3866+1G>A   Homozygous Severe to profound Nal et al., 2007 
c.3871C>T p.Leu1291Phe Motor Heterozygous Profound This study 
c.4176C>A p.Tyr1392* Motor Homozygous Severe to profound Nal et al., 2007 
c.4198G>A p.Val1400Met Motor Homozygous Severe to profound Cengiz et al., 2010 
c.4240G>A p.Glu1414Lys  Homozygous Profound Brownstein et al., 2011
c.4320+1G  Motor Heterozygous Severe to profound Woo et al,.2013 
c.4351G>A p.Asp1451Asn Motor Homozygous Severe to profound Nal et al., 2007 
c.4441T>C p.Ser1481Pro Motor Homozygous Severe to profound Cengiz et al., 2010 
c.4669A>G p.Lys1557Glu Motor Homozygous Severe to profound Nal et al., 2007 
c.4998C>A p.Cys1666* Motor Homozygous Severe to profound Belguith et al., 2009 
c.5117_5118del p.Gly1706Glufs*102 Motor Homozygous Severe to profound Nal et al., 2007 
c.5189T>C p.Leu1730Pro Motor Homozygous Severe to profound Nal et al., 2007 
c.5492G>T p.Gly1831Val Motor Homozygous Profound Kalay et al., 2007 
c.5808_5814del p.Arg1937Thrfs*10 IQ 2 Homozygous Severe to profound Cengiz et al., 2010 
c.5835T>G p.Tyr1945* IQ 2 Heterozygous Profound This study 
c.5913G>A   Heterozygous Severe to profound Gao et al,.2013 
c.6061C>T p.Gln2021*  ? Severe to profound Nal et al., 2007 
c.6217C>T p.Pro2073Ser MyTH4 1 Homozygous Severe to profound Shearer et al., 2009 
c.6308dup p.Ala2104Cysfs*19 MyTH4 1 Heterozygous Severe to profound Yang et al., 2013 
c.6340G>A p.Val2114Met MyTH4 1 Heterozygous Severe to profound Yang et al., 2013 
c.6371G>A p.Arg2124Gln MyTH4 1 Homozygous Severe to profound Shearer et al., 2009 
c.6437G>A p.Arg2146Gln MyTH4 1 Heterozygous Severe to profound Woo et al,.2013 
c.6614C>T p.Thr2205Ile MyTH4 1 Hemizygous *Residual hearing at low frequency Liburd et al., 2001 
c.6731G>A p.Gly2244Glu  Homozygous Severe to profound Nal et al., 2007 
c.6796G>A p.Val2266Met  Homozygous Severe to profound Nal et al., 2007 
c.6956+9C>G   Heterozygous Severe to profound Yang et al., 2013 
c.6956+9C>G   Heterozygous Severe to profound Yang et al., 2013 
c.7395+3G>C   Homozygous Severe to profound Belguith et al., 2009 
c.8148G>T p.Gln2716His  Homozygous Profound Liburd et al., 2001 
c.8158G>C p.Asp2720His  Homozygous Severe to profound Nal et al., 2007 
c.8324G>A p.Arg2775His  Heterozygous Severe to profound Yang et al., 2013 
c.8375T>C p.Val2792Ala  Heterozygous Severe to profound Gao et al,.2013 
c.8767C>T p.Arg2923* SH3 Heterozygous Severe to profound Yang et al., 2013 
c.8821_8822insTG p.Gly2941Valfs*94 SH3 Homozygous Severe to profound Nal et al., 2007 
c.8968-1G>C   Homozygous Profound Kalay et al., 2007 
c.9229+1G>T   Homozygous Severe to profound Belguith et al., 2009 
c.9478C>T p.Leu3160Phe MyTH4 2 Homozygous Severe to profound Nal et al., 2007 
c.9958_9961del p.Asp3320Thrfs*2 FERM Heterozygous Severe to profound Lezirovitz et al., 2008
c.9995_10002dup p.Ser3335Alafs*121 FERM Homozygous Severe to profound Cengiz et al., 2010 
c.10258_10260del p.Phe3420del FERM Heterozygous Severe to profound Yang et al., 2013 
c.10474C>T p.Gln3492* FERM Homozygous Severe to profound Nal et al., 2007 
c.10573del p.Ser3525Alafs*29 FERM Heterozygous Severe to profound Lezirovitz et al., 2008
c.10573del p.Ser3525Alafs*29 FERM Homozygous Severe to profound Lezirovitz et al., 2008
*Supplementary Fig. 1 
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Fig. 4. Pathogenicity of the p.L1291F
mutation. The mutation p.L1291F
would alter the structure of the actin-
binding site. (A) Wild type and (B)
mutation show different positions of
Met1793. Yellow area is the actin-
binding site and red area is ATP bind-
ing site. 
A                              B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
tional myosin XVA, which is encoded by MYO15A, are known 
to be responsible for DFNB3. The pathophysiology of deafness 
due to MYO15A mutations has been studied in shaker-2 mice, 
which contain homozygous recessive mouse mutations (sh2) in 
exon 20 (comprising the motor domain), and are regarded as a 
mouse homolog of human DFNB3 deafness (Cope et al., 1996; 
Probst et al., 1998). In a wild-type mouse, during auditory and 
vestibular hair cell development, myosin XVa is present at the 
tips of the stereocilia when the stereocilia bundle begins to 
develop its staircase architecture. Myosin XVa contributes to 
the differential elongation of each stereocilium (Tilney and 
Tilney, 1986; Tilney et al., 1992). In shaker-2 mice, myosin XVa 
is absent and the stereocilia are short and nearly equal in 
length. This leads to a loss of the staircase architecture of the 
stereocilia bundle, which is fundamental for sound transduction 
(Belyantseva et al., 2003; 2005). The loss of the staircase archi-
tecture of the stereocilia bundles is regarded as the main defect 
of the MYO15A mutation. 
Studies of the MYO15A mutation in humans have usually 
been performed in the Middle East, where consanguineous 
families are more common (Bashir et al., 2012; Belguith et al., 
2009; Brownstein et al., 2011; Cengiz et al., 2010; Diaz-Horta et 
al., 2012; Duman et al., 2011; Fattahi et al., 2012; Kalay et al., 
2007; Liburd et al., 2001; Nal et al., 2007; Shearer et al., 2009). 
However, as next-generation sequencing methods have be-
come more popular, MYO15A mutations have been reported 
from various parts of the world, and the importance of the 
MYO15A mutation has emerged (Besnard et al., 2014; Gao et 
al., 2013; Woo et al., 2013; Yang et al., 2013). The frequency of 
the MYO15A mutation was first reported by Friedman et al. 
(1995), who reported that 2% of the residents of Bengkala, Bali, 
had nonsyndromic autosomal recessive deafness due to the 
MYO15A mutation (Friedman et al., 1995). In 2002, Friedman et 
al. reported the frequency of the MYO15A mutation as 5% in 
Pakistan (Friedman et al., 2002). Recently, Fattahi et al. (2012) 
reported that in Iran, 5.71% of patients affected by nonsyndromic 
autosomal recessive deafness were associated with MYO15A. 
In Turkey, the frequency of the MYO15A mutation related with 
nonsyndromic autosomal recessive deafness has been re-
ported as 9.9%, which represents the second most common 
deafness gene (Duman et al., 2011). In our previous study, the 
frequency of the MYO15A mutation in nonsyndromic autosomal 
recessive deafness in patients requesting cochlear implants 
was 2.1%, which represents the fourth most common common 
deafness gene in Korea after SLC26A4, GJB2 and CDH23 
(Park et al., 2014). The frequency of the MYO15A mutation in 
Korea is not high as in the Middle East and this could be attri-
buted to the scarcity of consanguineous families in Korea. 
However, MYO15A remains an important deafness gene in the 
Korean population. 
Several MYO15A mutations have been reported according 
to the domains they affect. MYO15A mutations occur primarily 
in the motor domain, such as the p. L1291F (c.3871C>T) muta-
tion identified in this study. The motor domain contains the ATP- 
and actin-binding sites, the switch I and II helices, relay helix, 
SH3 helix, SH1/SH2 helix and a converter domain, and acts as 
a molecular motor. Therefore, it is conceivable that mutations in 
the motor domain would be more detrimental to the functioning 
of the protein and would be more prevalent than mutations in 
other myosin XVA domains. In this study, the 3D model created 
of the motor domain demonstrated how the p. L1291F 
(c.3871C>T) mutation altered the structure of the actin binding 
site and decreased the stability of actin binding. This could 
induce a disorder of the binding process between myosin and 
the actin filament and result in hearing loss. Recent successful 
purification of the motor domain of this protein by Bird et al. 
(2014) would contribute significantly to evaluation of pathogenic 
potential and mechanisms of variants located in this domain in 
the near future.  
The second mutation found was a nonsense mutation: 
p.Y1945* (c.5835T>G). It resides in the IQ2 domain, which is 
highly conserved throughout myosin and is known to contribute 
to the reinforcement of the motor function of myosin by increas-
ing conformational changes (Bahler and Rhoads, 2002). The 
p.Y1945* (c.5835T>G) mutation is predicted to truncate the 
translation of mRNA and result in myosin XVA that lacks half of 
its usual length. Several other nonsense mutations; p.Q2021*, 
p.S2661*, p.R2923* and p.Q3492*, located downstream to 
p.Y1945*, have already been reported to cause severe to pro-
found hearing loss (Duman et al., 2011; Nal et al., 2007; Yang 
et al., 2013). Therefore it seems likely that the p.Y1945* 
(c.5835T>G) mutation that results in a shorter protein product 
would definitely be pathogenic. 
MYO15A mutations have been regarded as leading to con-
genital severe to profound hearing loss (Belguith et al., 2009; 
Brownstein et al., 2011; Gao et al., 2013; Kalay et al., 2007; 
Liburd et al., 2001; Shearer et al., 2009; Wang et al., 1998;). 
Recently, conflicting descriptions of auditory phenotypes of the 
MYO15A mutation have been reported; Fattahi et al. (2012) 
reported seven mutations throughout the N-terminal extension, 
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motor domain, IQ domain and FERM domain of MYO15A and 
suggested that a down-sloping audioprofile was the defining 
audiologic feature of MYO15A-associated deafness. However, 
the audiograms included in the study by Fattahi et al. (2012) 
were not present in association with the affected domain, which 
precluded any genotype-phenotype correlations. Later, Bashir 
et al. (2012) proposed that the audiologic features of MYO15A 
mutations could be related to the affected domain. Specifically, 
they reported that almost all patients with mutations in exon 2 of 
MYO15A (p.E396Rfs*36 homozygote) had residual hearing at 
low frequencies but profound hearing loss at high frequencies. 
This feature has been observed in other studies in which muta-
tions in exon 2 (p.E1105*, p.R1113Vfs*12 and p.Y289* homo-
zygote), which encodes the N-terminal extension of MYO15A, 
resulted in better residual hearing at low frequencies, or even 
moderate to severe hearing loss compared with mutations in 
other regions of MYO15A (Cengiz et al., 2010; Nal et al., 2007). 
This observation has been confirmed by our analysis of audi-
ologic features of MYO15A mutations (Table 2). 
The possibility of less severe hearing loss associated with 
mutations residing in the N-terminal extension domain had 
already been suggested; Belyantseva et al. (2005) transfected 
a class 2 myosin XVa isoform that had no N-terminal extension, 
into shaker-2 hair cells, which had abnormally short stereocilia. 
In this explant culture experiment, elongation of the stereocilia 
occurred, and a wild-type-like staircase architecture of the hair 
bundle was obtained (Belyantseva et al., 2005). In other words, 
the staircase architecture of the hair bundle, the loss of which 
had been considered a crucial defect of DFNB3, was restored 
without N-terminal extension. Therefore, it is possible that the 
defect caused by mutations in exon 2 of MYO15A might be 
compensated for in part by the presence of the class 2 isoform 
without the N-terminal extension. Alternatively, alterations in the 
N-terminal extension domain, or even the absence of the class 
1 myosin XVA, might be related to functional problems or minor 
structural defects in the staircase architecture of the hair bundle 
(Nal et al., 2007), thereby leading to a milder auditory pheno-
type. Conversely, it can be hypothesized that if MYO15A muta-
tions affect a common region shared by both isoforms, other 
than exon 2, then the phenotype would be profound throughout 
all frequencies and have no, or minimal, residual hearing to 
trigger linguistic development, thereby requiring early cochlear 
implantation for speech development. The mutation identified in 
SB156-272 resided in exons 24 and 6. Based on the locations 
of the mutations, we predicted that SB156-272 would retain no 
residual hearing, which was later confirmed by behavioral audi-
ometry and electrically evoked auditory testing. Since minimal 
residual hearing would not allow language development even 
with a conventional hearing aid, simultaneous bilateral cochlear 
implantation was performed using a full-length electrode in 
SB156-272 at 11 months.  
Based on our findings and analysis of audiologic features of 
MYO15A mutations, we suggest a hypothetical genotype-
phenotype correlation whereby MYO15A mutations that affect 
domains other than the N-terminal domain, lead to profound 
SNHL throughout all frequencies, while mutations that affect the 
N-terminal domain, result in residual hearing at low frequencies, 
which could make contribution to language development and 
speech perception. Nowadays cochlear implantation, which 
converts sound into electrical pulse and stimulates the spiral 
ganglion or auditory nerve directly bypassing auditory hair cells, 
is the only auditory rehabilitation for severe to profound SNHL 
patients and gives a great benefit to them. As the technique of 
cochlear implantation has progressed and the indication of 
cochlear implantation has been expanded, severe to profound 
SNHL patients with residual hearing could also get a benefit 
from cochlear implantation. However cochlear implantation 
itself could damage auditory hair cells and basilar membrane 
and result in loss of residual hearing. Consequently the pres-
ence of residual hearing has been an important issue for coch-
lear implantation and the techniques of preserving residual 
hearing have been getting increased attention. Therefore our 
hypothetical genotype-phenotype correlation suggests a cus-
tomized treatment that preservation of residual hearing during 
cochlear implantation should be intended for those who carry 
mutations in the N-terminal domain and that the individuals with 
mutations elsewhere in MYO15A require early cochlear implan-
tation to timely initiate speech development. 
Here we identified two novel MYO15A mutations and sug-
gested hypothetical genotype-phenotype correlation. Basing 
decisions of appropriate timings and modality of auditory reha-
bilitation of DFNB3 deafness on the location of the mutations in 
MYO15A would provide a good model for customized auditory 
rehabilitation in this field.  
 
Note: Supplementary information is available on the Molecules 
and Cells website (www.molcells.org). 
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